A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

NCT07673029 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: GQ1005
DRUG: T-DM1

Sponsor

GeneQuantum Healthcare (Suzhou) Co., Ltd.